Patent ID: 9549942
Date: 2017-01-24
CPC Classifications: A23L,A61K

Claim:
1. A method for treating Alzheimer's dementia (Alzheimer's disease), comprising administering a pharmaceutical composition to a subject in need of treatment for Alzheimer's dementia (Alzheimer's disease), wherein the pharmaceutical composition is administered in an amount effective to decrease expression of BACE1 proteins, and wherein the pharmaceutical composition comprises at least one active ingredient selected from the group consisting of chlorhexidine, thioguanosine, mebendazole, fenbendazole, colchicine, farnesol, trimethobenzamide hydrochloride, disulfiram, azathioprine, mebeverine hydrochloride, zaprinast, tosufloxacin hydrochloride, efavirenz, thiostrepton, probenecid, entacapone, harmine hydrochloride, flunisolide, thimerosal, hexestrol, sulfaquinoxaline sodium salt, monensin sodium salt, raloxifene hydrochloride, 2-chloropyrazine, and topotecan.